The disability associated with Parkinson's disease (PD) is classically attributed to a range of motor symptoms, but people with PD also experience non-motor symptoms, ranging from cognitive and psychiatric problems including depression, apathy and anxiety, to sleep disorders, nocturia, sexual dysfunction, and faecal and urinary incontinence. Individuals have different experiences of PD, but in a recent survey of patients attending a UK PD clinic, sleep disturbance was the second most common non-motor symptom reported after balance problems [1] . Other studies have reported that 67-98% of patients are affected by sleeprelated problems and that these become increasingly prevalent as the disease progresses [2] .
Sleep disorders are important in Parkinson's disease
The disability associated with Parkinson's disease (PD) is classically attributed to a range of motor symptoms, but people with PD also experience non-motor symptoms, ranging from cognitive and psychiatric problems including depression, apathy and anxiety, to sleep disorders, nocturia, sexual dysfunction, and faecal and urinary incontinence. Individuals have different experiences of PD, but in a recent survey of patients attending a UK PD clinic, sleep disturbance was the second most common non-motor symptom reported after balance problems [1] . Other studies have reported that 67-98% of patients are affected by sleeprelated problems and that these become increasingly prevalent as the disease progresses [2] .
People with PD experience a wide range of sleeprelated symptoms, but in a recent pilot survey of members of the UK Parkinson's Disease Society, 41% of patients reported tiredness, fatigue and a lack of energy, while 30% said that they experienced frequent waking during the night and difficulty in sleeping, falling asleep and manoeuvring in bed [3] . Although advancing disease and the adverse effects of some drug treatments are contributory factors, disruption of nocturnal sleep is undoubtedly an important cause of excessive daytime sleepiness, which can be objectively verified in half the patients included in sleep laboratory studies [4] . Obstructive sleep apnoea syndromes are a common and treatable cause of disrupted sleep and daytime sleepiness in the elderly PD population [5] .
Sleepiness during the day results in impaired quality of life, and may be associated with cardiovascular risk [6] , dementia or cognitive impairment [7] , and an increased risk of accidents [8] . Conversely, studies of treatments designed to alleviate nocturnal symptoms have reported improvements in clinical global state, as well as reduction in painful dyskinesias, dystonia and nocturnal akinesia [9] . Improvement in nocturnal symptoms also has the potential to reduce caregiver burden, since sleep disturbance among PD patients commonly has a negative impact on the sleep of their spouses. Indeed, the impact of specific effects of PD on sleep may be at least as profound on the spouses as on the patients themselves. In one study of caregivers, sleep disturbance was reported by 90%, poor subjective sleep quality by 65% and sleep latency by 55%. Daytime dysfunction was also reported by 80%, though this was generally due to 'reduced enthusiasm' rather than actual difficulty in staying awake (80% versus 5%) [10] .
Two types of sleep disturbance have been reported among PD spouses: the first is associated with awakening during the night to help the patient and is predicted by the disease severity and the patient's sleep disturbance, while the second is predicted by the spouse's own level of stress and depression [11] . The negative impact of PD-related sleep disturbance on both patients and their family caregivers warrants aggressive intervention, but the approach to treatment will be influenced by the aetiology of the symptoms in each patient.
Sleep disorders are under-diagnosed and under-treated
The factors affecting sleep and/or wakening or the sleep/ wake continuum are complex in PD patients and include both disease-related and treatment-related factors (Table 1) . However, it is increasingly recognised that dopamine is involved in the sleep/wake cycle [12] , and in PD the progressive death of dopaminergic cells may contribute to two groups of disorders that adversely affect nocturnal sleep: (i) state dysregulation, resulting in disconnection between normal homeostatic mechanisms so that patients nap during the day with rapid eye movement (REM) sleep and also sleep at night; and (ii) state-dependent motor dysregulation, where abnormal motor behaviour disturbs the patient at night, with periodic leg movements, sustained tonic EMG activity in REM, and phasic EMG activity in REM and NREM.
Because of the complexities of the aetiology, it is rarely possible to identify one causal factor for a patient's nocturnal symptoms, but assessment that includes a detailed history will help to identify possible treatment options. It is essential to ask patients and their family caregivers specifically about sleep-related problems, since this information may not be volunteered spontaneously. In the survey of PD patients discussed above, 52% responded positively when specifically asked about sleep disturbance compared with 29% who spontaneously reported difficulties in sleeping.
All non-motor symptoms are currently under-recognised even by PD specialists; one study showed that neurologists failed to identify sleep disturbance in over 40% of routine consultations [13] . The self-administered Epworth Sleepiness Scale (ESS) is helpful in assessing sleep problems in PD [14] .
The ESS is confined to assessing the patient's level of daytime sleepiness, but this can now be combined with the more recently developed Parkinson's Disease Sleep Scale (PDSS) to provide a more general assessment of sleep dysfunction in PD [15] . The PDSS consists of 15 items to be completed by the patient or interviewer, with input from the spouse/partner as appropriate, devised following an audit of nocturnal symptoms described by more than 500 PD patients and caregivers attending a regional movement disorders clinic (Table 2) .
Treatment options
The PDSS can be used to identify the individual's sleeprelated symptoms at baseline, and to assess the impact of treatment. These are both important since the treatment of sleep disorder symptoms is likely to be inadequate if treatment does not address the causal factors.
Both patients and caregivers can benefit from several simple, practical sleep hygiene measures designed to generally improve sleep (Table 3) , but most patients are likely to also need pharmacological treatment targeted at the causes of their nocturnal symptoms.
Nocturia affects up to 70% of people with PD [16] , and may be improved by treatment with oxybutynin or tolterodine if it is caused by detrusor instability, although anticholinergic drugs for bladder dysregulation may induce or worsen confusion in the PD population. Patients may also experience early morning postural hypotension, which may respond to head-up tilt of the bed at night, nocturnal desmopressin nasal spray and avoidance of diuretics, antihypertensives and vasodilators.
Depression is also common in PD, affecting up to 40% of patients [16] , and may alter sleep patterns. Selective serotinin reuptake inhibitors (SSRIs) are frequently used, though insomnia is a known adverse effect and their use is based on clinical experience rather than blinded, randomised studies using carefully defined populations of PD patients. Possible alternatives are the sedating tricyclic antidepressants, while selegiline and long-acting dopamine agonists (DAs) may also have antidepressant action.
The management of nocturnal neuropsychiatric symptoms such as psychoses, REM behaviour disorder, panic attacks, sleep talking, confusion and hallucinations is extremely challenging. Drug-induced psychosis should be excluded, while REM behaviour disorder may respond to clonazepam. Short-acting benzodiazepines help to improve panic attacks during 'on' periods, while dopaminergic agents may alleviate symptoms during 'off' periods, although some patients may require careful reduction in dopaminergic therapy. Hallucinations are difficult to treat because typical neuroleptics exacerbate Parkinsonism and some patients may not respond well to atypical drugs even when initiated at very low doses. Quetiapine may be an option. If the sleep hygiene measures fail to improve insomnia, appropriate pharmacological management should be considered. Firstly, bearing in mind the high proportion of PD patients with cognitive impairment, it is important to maintain as simple a treatment regime as possible, by considering treatment options with a once daily formulation and oral administration, such as cabergoline, the longest-acting of the DAs. Short-acting benzodiazepines may be helpful for sleep-onset insomnia, while sleep-maintenance insomnia may respond to long-acting DAs [9] , by overcoming nocturnal 'off' periods. Treatment strategies that provide sustained dopaminergic stimulation, with long-acting DAs, controlledrelease levodopa with a catechol-O-methyltransferase (COMT) inhibitor or long-acting apomorphine infusion, can also be used to manage nocturnal fluctuations. The effectiveness of this strategy will be improved if patients are advised to avoid high-protein meals at night to promote gastric absorption, though domperidone may be required if delayed gastric emptying remains a problem. Restless legs syndrome similarly responds to apomorphine infusion [17] and oral dopamine agonists. These products are not presently licensed for this indication in the UK.
Conclusion
At present, despite their high prevalence, sleep disorders are under-diagnosed and may be inadequately treated in people with PD. Raised awareness and a more aggressive approach to intervention are warranted, as nocturnal symptoms can have a seriously adverse effect on the quality of life of both patients and family carers. Patients may not appreciate that PD contributes to their sleep problems, so clinicians and PD specialist nurses need to take the initiative and raise the issue at each routine consultation, using the PDSS to assess the nature of the sleep disorder and initiate measures that will promote 24-hour control of symptoms. Finally, since PD is progressive, management options should be regularly reviewed to provide patients and their caregivers with the most effective treatment package that promotes a good night's sleep. Table 3 . Advice for patients on how to improve sleep-related problems 
